A Metabolomics-based Study to Explore the Mechanism of Remission of Metabolic Syndrome Radical Resection of Colorectal Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
Colorectal cancer patients with hypertension: Colorectal cancer patients with hypertension
Colorectal cancer patients with diabetes: Colorectal cancer patients with diabetes
Colorectal cancer patients with fatty liver: Colorectal cancer patients with fatty liver
Study summary
1. Analysis of preoperative and postoperative metabolite changes: Through metabolomics technology, the changes of preoperative and postoperative metabolites in patients with colorectal cancer complicated with metabolic syndrome such as hypertension and diabetes were systematically analyzed, and the key metabolites related to postoperative remission were found.
2. Explore the influencing factors of postoperative remission of metabolic syndrome: Combined with clinical data, the association between various metabolites and the degree of postoperative remission was evaluated, and the main factors affecting postoperative remission were determined.
To reveal the mechanism of the remission of metabolic syndrome after surgery: To clarify the metabolic pathways and mechanisms involved in the remission of metabolic syndrome after surgery through multi-level metabolomics analysis, and to provide a new theoretical basis for the development of tumor metabolic surgery.
Eligibility
Primary outcome measure(s)
- Metabolic disease remission — From date of surgery until the date of first documented postoperative complication, assessed up to 2 months after surgery.
Metabolic disease remission was defined as any remission of hypertention, diabetes, or fatty liver measured 2 months after surgery. Hypertension remission was defined as arterial blood pressure less than 140/90 mmHg measured postoperatively in patients with preoperative comorbid hypertension. Diabetes remission was defined as fasting blood glucose less than 6 mmol/L measured postoperatively in patients with preoperative comorbid diabetes. Fatty liver remission was defined as liver function in the normal range measured by postoperative blood tests in patients with preoperative comorbid fatty liver.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Chongqing medical university | Chongqing | Chongqing Municipality |
More Dong Peng trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06710314 on ClinicalTrials.gov ↗ ← All trials in China